Safety · Source update
New ACOG guidance addresses GLP-1 medicines before pregnancy and during breastfeeding
Source context: Read the linked original research or registry entry for study status and limitations.
With more people of reproductive age using GLP-1 medications for weight loss or diabetes, questions about planning a pregnancy or restarting treatment while breastfeeding have become increasingly common. On October 23, 2026, the American College of Obstetricians and Gynecologists (ACOG) released new clinician guidance emphasizing preconception planning, avoidance during pregnancy and individualized discussions postpartum.
What changed this week?
ACOG issued guidance for obstetric clinicians on discussing GLP-1 receptor agonists before, during and after pregnancy. The new advice responds to widespread use of these medications and significant gaps in evidence about fetal exposure, breast milk, infant growth and long-term outcomes.
What if someone is planning to become pregnant?
The guidance advises discussing medication discontinuation before conception, commonly one to two months in advance, because these medicines are not recommended in pregnancy. The exact interval may depend on the particular drug and its approved labeling. Do not stop or change treatment for diabetes without arranging an appropriate plan with the prescribing team.
Should GLP-1 medicines be used during pregnancy?
ACOG advises against use during pregnancy because safety evidence remains inadequate. If pregnancy occurs while someone is taking a GLP-1, they should contact their obstetric and prescribing clinicians promptly for an individualized assessment rather than relying on social-media advice.
What does the guidance say about breastfeeding?
The guidance allows shared decision-making in selected postpartum circumstances but does not establish that GLP-1 injections are universally safe while nursing. Reporting on the advisory notes caution during the first month of life and in preterm infants, and recommends close infant weight monitoring if treatment is considered. Evidence on milk production, nutrition and longer-term child outcomes remains limited.
Are injections and pills treated the same way?
No. Oral GLP-1 formulations may contain absorption-enhancing ingredients for which breastfeeding safety information is especially sparse. Available reports on the guidance advise avoiding oral GLP-1s while nursing. A medication-specific discussion is essential; assumptions about one injectable product should not be generalized to all formulations.
What does this mean for people using MyDosePro?
Medication comparisons and price calculators cannot determine whether a treatment is appropriate during pregnancy or lactation. Anyone planning pregnancy, pregnant or breastfeeding should review the current FDA label for their exact medication with their obstetric clinician and prescribing team. ACOG's recommendations are guidance for shared decisions, not a guarantee of safety.
The bottom line
GLP-1 weight-loss medications should not be treated as safe during pregnancy. Decisions around postpartum use and breastfeeding require clinician-led discussions; early evidence is not proof of safety.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-10-23. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceOctober 23 reporting on the American College of Obstetricians and Gynecologists guidance ↗
Additional evidenceSource event or update: 2026-10-23. Our interpretation is educational and does not replace medical or insurance advice.